Tags

Type your tag names separated by a space and hit enter

Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
Clin Exp Nephrol. 2014 Oct; 18(5):755-62.CE

Abstract

BACKGROUND

Erythropoiesis-stimulating agents (ESAs) are standard therapy for chronic kidney disease (CKD) patients with renal anemia. However, few studies have compared the effects of different ESAs on anemia in identical pre-dialysis CKD patients.

METHODS

Seventy-nine patients who switched from epoetin beta to darbepoetin alfa (Group 1), and 82 patients who switched from darbepoetin alfa to epoetin beta pegol (Group 2) were enrolled in this study. Clinical and laboratory parameters were assessed for 6 months before and after switching ESAs. The prevalence of adverse events, the dose conversion ratio of ESAs, and the frequency of ESA administration were also analyzed.

RESULTS

Analysis of variance showed that switching ESAs did not significantly change hemoglobin levels for the study duration in both groups (mean hemoglobin 10.3-10.5 g/dL in Group 1 and 10.4-10.7 g/dL in Group 2). Estimated glomerular filtration rate, blood pressure, transferrin saturation, ferritin, and albumin remained constant in both groups. The prevalence of adverse effects was quite low (0-3.8 %) during both 6-month study periods. The mean dose conversion ratio for epoetin beta:darbepoetin alfa was 163.7 units:1 μg and for darbepoetin alfa:epoetin beta pegol was 1.08 μg:1 μg. The intervals of ESA administration significantly differed (epoetin beta pegol > darbepoetin alfa > epoetin beta).

CONCLUSIONS

Epoetin beta, darbepoetin alfa, and epoetin beta pegol are effective and well-tolerated agents for managing anemia in Japanese pre-dialysis CKD patients. The intervals of ESA administration to maintain a patient's target hemoglobin were longer in the order of epoetin beta pegol > darbepoetin alfa > epoetin beta.

Authors+Show Affiliations

Department of Nephrology, Shuuwa General Hospital, 1200 Yahara-Shinden, Kasukabe, Saitama, 344-0035, Japan, kuwaharam@shuuwa-gh.or.jp.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

24317507

Citation

Kuwahara, Michio, et al. "Effects of Three Kinds of Erythropoiesis-stimulating Agents On Renal Anemia in Japanese Non-dialysis Chronic Kidney Disease Patients." Clinical and Experimental Nephrology, vol. 18, no. 5, 2014, pp. 755-62.
Kuwahara M, Hasumi S, Mandai S, et al. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Clin Exp Nephrol. 2014;18(5):755-62.
Kuwahara, M., Hasumi, S., Mandai, S., Tanaka, T., Shikuma, S., Akita, W., Mori, Y., & Sasaki, S. (2014). Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Clinical and Experimental Nephrology, 18(5), 755-62. https://doi.org/10.1007/s10157-013-0919-0
Kuwahara M, et al. Effects of Three Kinds of Erythropoiesis-stimulating Agents On Renal Anemia in Japanese Non-dialysis Chronic Kidney Disease Patients. Clin Exp Nephrol. 2014;18(5):755-62. PubMed PMID: 24317507.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. AU - Kuwahara,Michio, AU - Hasumi,Syoko, AU - Mandai,Shintaro, AU - Tanaka,Tomomi, AU - Shikuma,Satomi, AU - Akita,Wataru, AU - Mori,Yoshihiro, AU - Sasaki,Sei, Y1 - 2013/12/07/ PY - 2013/05/23/received PY - 2013/11/21/accepted PY - 2013/12/10/entrez PY - 2013/12/10/pubmed PY - 2015/6/30/medline SP - 755 EP - 62 JF - Clinical and experimental nephrology JO - Clin Exp Nephrol VL - 18 IS - 5 N2 - BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are standard therapy for chronic kidney disease (CKD) patients with renal anemia. However, few studies have compared the effects of different ESAs on anemia in identical pre-dialysis CKD patients. METHODS: Seventy-nine patients who switched from epoetin beta to darbepoetin alfa (Group 1), and 82 patients who switched from darbepoetin alfa to epoetin beta pegol (Group 2) were enrolled in this study. Clinical and laboratory parameters were assessed for 6 months before and after switching ESAs. The prevalence of adverse events, the dose conversion ratio of ESAs, and the frequency of ESA administration were also analyzed. RESULTS: Analysis of variance showed that switching ESAs did not significantly change hemoglobin levels for the study duration in both groups (mean hemoglobin 10.3-10.5 g/dL in Group 1 and 10.4-10.7 g/dL in Group 2). Estimated glomerular filtration rate, blood pressure, transferrin saturation, ferritin, and albumin remained constant in both groups. The prevalence of adverse effects was quite low (0-3.8 %) during both 6-month study periods. The mean dose conversion ratio for epoetin beta:darbepoetin alfa was 163.7 units:1 μg and for darbepoetin alfa:epoetin beta pegol was 1.08 μg:1 μg. The intervals of ESA administration significantly differed (epoetin beta pegol > darbepoetin alfa > epoetin beta). CONCLUSIONS: Epoetin beta, darbepoetin alfa, and epoetin beta pegol are effective and well-tolerated agents for managing anemia in Japanese pre-dialysis CKD patients. The intervals of ESA administration to maintain a patient's target hemoglobin were longer in the order of epoetin beta pegol > darbepoetin alfa > epoetin beta. SN - 1437-7799 UR - https://www.unboundmedicine.com/medline/citation/24317507/Effects_of_three_kinds_of_erythropoiesis_stimulating_agents_on_renal_anemia_in_Japanese_non_dialysis_chronic_kidney_disease_patients_ DB - PRIME DP - Unbound Medicine ER -